

Bone Therapeutics officially opens its new headquarters in Gosselies

The new 3000m² facility is part of a larger project, known as PWTC or the “Plateforme Wallonne de Thérapie Cellulaire”

Gosselies, Belgium, 24 April 2015 - BONE THERAPEUTICS, the bone cell therapy company addressing high unmet medical needs in the field of bone fracture repair and bone fracture prevention, today announces the official opening of its new headquarters at the Gosselies Biopark in Belgium. Bone Therapeutics’ new facility is being officially opened in the presence of Mr Paul Magnette, Minister-President of Wallonia, and Mr Jean-Claude Marcourt, Vice-President of the Walloon Government.

Bone Therapeutics is undertaking a phased move to the new site which will eventually host all of its operational activities. The administrative and R&D departments will move in the coming days. In mid-2016, the production activities will also be transferred to the new facilities, where initially two manufacturing units will be available. From 2018 onwards, four additional production units will be commissioned to meet the production requirements for the pre-commercial and initial commercial demand for Bone Therapeutics’ unique products. Importantly, additional production units can be added to the facility to ensure manufacturing capacity can meet future demand.

The Biopark is bringing the advantages of a unique and innovative high-tech cluster to cater for the needs of the increasing number of Walloon based cell therapy and biotech companies. Bone Therapeutics has joined forces with cell therapy company Promethera Biosciences to build this new facility at this unique location. The new 3000m² facility is part of a larger project, known as PWTC or “Plateforme Wallonne de Thérapie Cellulaire”. PWTC will be operated by three dedicated service companies, SISE (Société d’Infrastructures, de Services et d’Energies), SCTS (Skeletal Cell Therapy Support) and HCTS (Hepatic Cell Therapy Support).

Enrico Bastianelli, CEO of Bone Therapeutics, commented: *“We are excited to be starting the move to our new headquarters, situated in the heart of this thriving Belgian biotech cluster. Following the rapid expansion of our clinical programmes last year and the recent IPO, this is an important step to underpin the Company’s commercial readiness and the continued growth of the business.”*

Paul Magnette, Minister-President of Wallonia and Mayor of Charleroi said: *“The PWTC provides great added value for Wallonia and highlights the region’s passion for innovation. The new facility that is being opened here today offers major benefits for cell therapy companies and ensures a leadership position for Wallonia in the significant field of cell therapy.”*

-Ends-

About Bone Therapeutics

Bone Therapeutics is a leading biotechnology company specializing in the development of cell therapy products intended for bone fracture repair and fracture prevention. The current standard-of-care in this field involves major surgeries and long recovery periods. To overcome these problems, Bone Therapeutics is developing a range of innovative regenerative products containing osteoblastic/bone-forming cells, administrable via a minimally invasive percutaneous technique; a unique proposition in the market.

PREOB[®], Bone Therapeutics' autologous bone cell product, is currently in pivotal Phase IIB/III clinical studies for two indications: osteonecrosis and non-union fractures, and in Phase II for severe osteoporosis. ALLOB[®], its allogeneic "off-the-shelf" bone cell product, is in Phase II for the treatment of delayed-union fractures and lumbar fusion for degenerative disease of the spine. The Company also runs preclinical research programs and develops novel product candidates.

Founded in 2006, Bone Therapeutics is headquartered in Gosselies (South of Brussels, Belgium). Bone Therapeutics' regenerative products are manufactured to the highest GMP standards and are protected by a rich IP estate covering 9 patent families. Further information is available at www.bonetherapeutics.com.

For more information, please contact:

Bone Therapeutics SA

Tel: +32 (0)2 529 59 90

Enrico Bastianelli, Chief Executive Officer/ Wim Goemaere, Chief Financial Officer

investorrelations@bonetherapeutics.com

For Belgium and International Media Enquiries

Consilium Strategic Communications

Tel: +44 (0) 20 3709 5701

Amber Bielecka, Jessica Hodgson, Lindsey Neville and Hendrik Thys

bonetherapeutics@consilium-comms.com

For French Media and Investor Enquiries

NewCap Investor Relations & Financial Communications

Tel: + 33 (0)1 44 71 94 94

Pierre Laurent and Antoine Denry

bone@newcap.fr

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change

in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.